Beth Israel Deaconess Medical Center patents new DYRK1A inhibitors
Dec. 20, 2024
Beth Israel Deaconess Medical Center Inc. has disclosed dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and more.